Oragenics Inc Sample Contracts

Lease Annual Net Annual Net Monthly Payment Year: Rent/RSF: Rent: Rent:
Lease • March 14th, 2005 • Oragenics Inc • Pharmaceutical preparations
AutoNDA by SimpleDocs
WHEREAS:
Common Stock Purchase Agreement • May 23rd, 2005 • Oragenics Inc • Pharmaceutical preparations • Florida
DEFINITIONS
Securities Purchase Agreement • March 10th, 2006 • Oragenics Inc • Pharmaceutical preparations • Florida
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • April 10th, 2018 • Oragenics Inc • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of April 6, 2018, between Oragenics, Inc., a Florida corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

BUSINESS LOAN AGREEMENT
Business Loan Agreement • May 13th, 2005 • Oragenics Inc • Pharmaceutical preparations • Florida
Oragenics, Inc. and Continental Stock Transfer & Trust Company, as Warrant Agent Warrant Agency Agreement Dated as of July 17, 2018
Warrant Agency Agreement • July 17th, 2018 • Oragenics Inc • Pharmaceutical preparations • New York

WARRANT AGENCY AGREEMENT, dated as of July 17, 2018 (“Agreement”), between Oragenics, Inc., a Florida corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”).

Form of Representative’s Warrant Agreement WARRANT TO PURCHASE COMMON STOCK ORAGENICS, INC.
Oragenics Inc • March 1st, 2024 • Pharmaceutical preparations

THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ____, 2024 (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(g)(8)(A), prior to at 5:00 p.m. (New York time) on the date that is five (5) years following the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oragenics, Inc., a Florida corporation (the “Company”), up to ______ shares of Common Stock, par value $0.001 per share, of the Company (the “Warrant Shares”), as subject to adjustment hereunder. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

ORAGENICS, INC. UNDERWRITING AGREEMENT 14,189,189 Shares of Common Stock
Underwriting Agreement • November 24th, 2020 • Oragenics Inc • Pharmaceutical preparations • New York

Oragenics, Inc., a company incorporated under the laws of Florida (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Oragenics, Inc., the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriter named in Schedule I hereto (the “Underwriter”), an aggregate of 14,189,189 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Company also proposes to sell to the Underwriter, upon the terms and conditions set forth herein, up to an additional 2,128,378 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are collectively referred to as the “Shares.”

COMMON STOCK PURCHASE WARRANT ORAGENICS, INC.
Common Stock Purchase • July 17th, 2018 • Oragenics Inc • Pharmaceutical preparations • New York

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after , 2018 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on , 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oragenics, Inc., a Florida corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s right to elect to receive a Warrant in certifi

UNDERWRITING AGREEMENT between ORAGENICS, INC. and THINKEQUITY LLC as Representative of the Several Underwriters ORAGENICS, INC.
Underwriting Agreement • March 1st, 2024 • Oragenics Inc • Pharmaceutical preparations • New York

The undersigned, Oragenics, Inc., a corporation formed under the laws of the State of Florida (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:

16,666,668 SHARES OF COMMON STOCK 8,333,334 SERIES 1 WARRANTS AND 8,333,334 SERIES 2 WARRANTS OF ORAGENICS, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • March 25th, 2019 • Oragenics Inc • Pharmaceutical preparations • New York

The undersigned, Oragenics, Inc., a company incorporated under the laws of Florida (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Oragenics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which H.C. Wainwright & Co., LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.

WHEREAS:
Registration Rights Agreement • May 23rd, 2005 • Oragenics Inc • Pharmaceutical preparations • Florida
COMMERCIAL SECURITY AGREEMENT
Commercial Security Agreement • May 13th, 2005 • Oragenics Inc • Pharmaceutical preparations • Florida
oragenics, INC. COMMON STOCK SALES AGREEMENT
Sales Agreement • February 1st, 2021 • Oragenics Inc • Pharmaceutical preparations • New York

Oragenics, Inc., a Florida corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners, as follows:

AT THE MARKET OFFERING AGREEMENT
The Market Offering Agreement • February 24th, 2023 • Oragenics Inc • Pharmaceutical preparations • New York

Oragenics, Inc., a corporation organized under the laws of Florida (the “Company”), confirms its agreement (this “Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Manager”) as follows:

FORM OF SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • December 28th, 2020 • Oragenics Inc • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of December 23, 2020, and is between Oragenics, Inc., a company incorporated under the laws of Florida (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

COMMON STOCK PURCHASE WARRANT ORAGENICS, INC.
Oragenics Inc • April 10th, 2018 • Pharmaceutical preparations

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 6, 2018 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 10, 2023 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oragenics, Inc., a Florida corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

THIS WARRANT AND ANY SHARES ACQUIRED UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH...
Common Stock Purchase Warrant • May 4th, 2020 • Oragenics Inc • Pharmaceutical preparations • Florida

This Warrant is issued pursuant to that certain Stock Purchase Agreement dated May 1, 2020 by and among the Company and the stockholder (the “Purchase Agreement”).

Oragenics, Inc.
Oragenics Inc • December 28th, 2020 • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • January 13th, 2006 • Oragenics Inc • Pharmaceutical preparations • Florida

This Registration Rights Agreement (this “Agreement”) is made and entered into as of November 20, 2005, by and among Oragenics, Inc, a Florida corporation (the “Company”), and the persons signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).

AutoNDA by SimpleDocs
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • April 9th, 2003 • Oragenics Inc • Pharmaceutical preparations • Florida

THIS REGISTRATION RIGHTS AGREEMENT (the "Agreement") is made and entered into as of the ____ day of April, 2002, by and among Oragenics, Inc., a Florida corporation ("Oragenics") and the purchasers listed on Schedule I hereto (each such person a "Seller" and, collectively, the "Sellers").

TRANSFER AGENT, REGISTRAR AND DIVIDEND DISBURSING AGENT AGREEMENT
Disbursing Agent Agreement • December 23rd, 2002 • Oragenics Inc • Pharmaceutical preparations • British Columbia

This agreement witnesses that in consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties covenant and agree as follows:

EXCLUSIVE CHANNEL COLLABORATION AGREEMENT
Exclusive Channel Collaboration Agreement • June 11th, 2015 • Oragenics Inc • Pharmaceutical preparations • New York

THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of June 9, 2015 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876, U.S.A. (“Intrexon”), Intrexon Actobiotics NV, a naamloze vennootschap under Belgian law with registered offices at Technologiepark 4, 9052 Zwijnaarde (CBE no. 0882.251.820 (Ghent), Belgium (“Actobiotics”), and ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634, U.S.A. (“Oragenics”). Intrexon and Actobiotics together on the one hand and Oragenics on the other hand may be referred to herein individually as a “Party”, and collectively as the “Parties.”

WARRANT INDENTURE _____________________________________________________________ _____________________________ THIS WARRANT INDENTURE is dated as of March 28, 2003, BETWEEN: ORAGENICS, INC., a Florida company located at 12085 Research Drive, Alachua,...
Warrant Indenture • May 5th, 2003 • Oragenics Inc • Pharmaceutical preparations • British Columbia

COMPUTERSHARE TRUST COMPANY OF CANADA, a trust company incorporated under the laws of Canada and authorized to carry on trust business in the Province of British Columbia and having a branch office at 4th Floor, 510 Burrard Street, Vancouver, British Columbia, V6C 3B9

AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • November 9th, 2017 • Oragenics Inc • Pharmaceutical preparations • New York

This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 8th day of November, 2017 by and among Oragenics, Inc., a Florida corporation (the “Company”), and each of the several holders of Registrable Securities (as defined below) signatory hereto (each such holder, a “Holder” and, collectively, the “Holders”). Capitalized terms used herein have the respective meanings ascribed thereto in that certain Securities Purchase Agreement dated November 8, 2017 by and among the Company and the other parties signatory thereto (the “Purchase Agreement”) unless otherwise defined herein.

ESCROW AGREEMENT UNDER NATIONAL POLICY 46-201
Escrow Agreement • October 16th, 2002 • Oragenics Inc • British Columbia

This Agreement is being entered into by the Parties under National Policy 46-201 Escrow for Initial Public Offerings (the Policy) in connection with the proposed distribution (the IPO), by the Issuer, an emerging issuer, of 2,000,000 Units (the "Units") consisting of one share of common stock (the "Shares"), one half of one Series A warrant (the "Series A Warrants") and one half of one Series B warrant (the "Series B Warrants") by prospectus.

POOLING AGREEMENT
Pooling Agreement • April 9th, 2003 • Oragenics Inc • Pharmaceutical preparations • British Columbia

This Agreement is being entered into by the Parties in connection with the proposed distribution (the IPO), by the Issuer, of 2,000,000 Units (the "Units") consisting of one share of common stock (the "Shares"), one half of one Series A warrant (the "Series A Warrants") and one half of one Series B warrant (the "Series B Warrants") by prospectus.

EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • December 29th, 2023 • Oragenics Inc • Pharmaceutical preparations

This Executive Employment Agreement (the “Agreement”) dated as of December 28, 2023 (the “Effective Date”), is by and between ORAGENICS, INC., a Florida corporation, (the “Company”), and JOSEPH MICHAEL REDMOND (the “Executive”).

ORAGENICS, INC. SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • November 9th, 2017 • Oragenics Inc • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of November 8, 2017, among Oragenics, Inc., a Florida corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

ORAGENICS, INC. STOCK PURCHASE AGREEMENT
Stock Purchase Agreement • June 30th, 2016 • Oragenics Inc • Pharmaceutical preparations • Florida

This Stock Purchase Agreement (this “Agreement”) is made and entered into as of June 30, 2016 (the “Effective Date”), among Oragenics, Inc., a Florida corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

Form of Warrant
Common Stock Purchase • November 9th, 2017 • Oragenics Inc • Pharmaceutical preparations • New York

This Warrant is issued pursuant to that certain Securities Purchase Agreement dated November 8, 2017 by and among the Company and the other parties signatory thereto (the “Purchase Agreement”).

TRANSITION SERVICES AGREEMENT
Transition Services Agreement • June 27th, 2016 • Oragenics Inc • Pharmaceutical preparations • Florida

THIS TRANSITION SERVICES AGREEMENT (this “Agreement”) is entered into as of June 24, 2016 (the “Effective Date”), by and between ProBiora Health, LLC, a Delaware limited liability company (the “Recipient”) and Oragenics, Inc., a Florida corporation (“Provider” and together with the Recipient, the “Parties”).

Time is Money Join Law Insider Premium to draft better contracts faster.